IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2026-05-29
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, and best dose of IACS-6274 with or without
pembrolizumab in treating patients with solid tumors that have spread to other places in the
body (advanced). IACS-6274 may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Giving IACS-6274 with or without pembrolizumab may help to control
the disease.